Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for buccal, oral, and sublingual use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapin Actavis is a NaSSA antidepressant used to manage depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves mood. - Depressive episodes with insomnia: helps restore sleep continuity. - Depressive disorder with anxiety: alleviates anxiety and tension associated with depression.

Mirtazapin Actavis may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypotension - Hepatic dysfunction - Suicidal ideation, especially early in treatment

Before prescribing Mirtazapin Actavis, clinicians should consider several safety aspects. - Pregnancy: Category B – use only if benefit outweighs risk. - Elderly patients: monitor for increased sedation and falls. - Hepatic impairment: dose adjustment may be required. - Concomitant CNS depressants: avoid excessive sedation. - History of bipolar disorder: risk of mood switching. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Mirtazapin Actavis can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels. - CNS depressants (e.g., benzodiazepines, alcohol): heightened sedation.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for additive serotonergic effects. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Antihypertensives: possible additive hypotensive effect.